SLC2A1 and uterine corpus sarcoma: Currently, 18F-FDG is widely used to evaluate regional glucose metabolism in a variety of tumors, including uterine sarcomas [19, 20], and high correlations have been found between 18F-FDG uptake and GLUT-1 expression in most malignant tumors [21–23].